SCHEDULE 13D/A: Edesa Biotech Insider Dr. Pardeep Nijhawan Boosts Stake to 19.99% Through Private Placement and RSU Grants

Dr. Pardeep Nijhawan and affiliated entities have increased their beneficial ownership in Edesa Biotech, Inc. to 19.99% through recent restricted share unit grants and a private placement of Series B-1 Convertible Preferred Shares.

Summary

• Dr. Pardeep Nijhawan, along with affiliated entities, now beneficially owns an aggregate of 1,596,581 Common Shares of Edesa Biotech, Inc., representing approximately 19.99% of the Issuer's outstanding Common Shares.
• This beneficial ownership includes shares held directly by Dr. Nijhawan, as well as shares held by Pardeep Nijhawan Medicine Professional Corporation, The Digestive Health Clinic Inc., 1968160 Ontario Inc., and The New Nijhawan Family Trust 2015.
• The calculation of Dr. Nijhawan's 19.99% stake is based on 6,936,404 Common Shares outstanding as of February 14, 2025, plus additional shares underlying vested share options (49,728), vested restricted share units (75,435), vested warrants (359,170), Series A-1 Preferred Shares (435,414), and Series B-1 Preferred Shares (132,433) deemed outstanding for this reporting person.
• The reported holdings exclude 388,400 Common Shares underlying Series B-1 Preferred Shares held by Pardeep Nijhawan, which are subject to a 19.99% beneficial ownership blocker.
• Since November 1, 2024, Dr. Pardeep Nijhawan received several grants of restricted share units (RSUs) that vested in full upon grant, totaling 27,790 RSUs.
• On February 12, 2025, Edesa Biotech entered into a Securities Purchase Agreement with purchasers, including Pardeep Nijhawan, for a private placement of 100 shares of newly designated Series B-1 Convertible Preferred Shares.
• Each Series B-1 Preferred Share has a stated value and purchase price of $10,000, and is initially convertible into approximately 520,833 Common Shares at a conversion price of $1.92 per share.
• Pardeep Nijhawan Medicine Professional Corporation beneficially owns 1,119,981 Common Shares, representing 14.5% of the Issuer's outstanding Common Shares.
• The Digestive Health Clinic Inc. beneficially owns 32,013 Common Shares (0.5%), 1968160 Ontario Inc. beneficially owns 53,104 Common Shares (0.8%), and The New Nijhawan Family Trust 2015 beneficially owns 48,914 Common Shares (0.7%).

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to a significant insider increasing their stake and participating in a capital raise, indicating confidence. However, it's a factual ownership update, not a performance report, so it's not overwhelmingly positive.

Positives

• Dr. Pardeep Nijhawan, a key insider and CEO, has significantly increased his beneficial ownership in Edesa Biotech, demonstrating continued confidence in the company.
• The private placement of Series B-1 Preferred Shares indicates a capital infusion into the company, with Dr. Nijhawan participating as a purchaser.
• The receipt of vested restricted share units by Dr. Nijhawan aligns management's interests with shareholder value.

Negatives

• The 19.99% beneficial ownership blocker on the conversion of Series B-1 Preferred Shares limits Dr. Nijhawan's immediate ability to convert all his preferred shares into common shares, potentially capping his direct voting power from these specific shares at that threshold.

Risks

• The 19.99% beneficial ownership blocker on the conversion of Series B-1 Preferred Shares means that Dr. Nijhawan cannot convert portions of these shares if it would result in him beneficially owning more than 19.99% of the outstanding common shares immediately after conversion, which could affect liquidity or control dynamics related to these specific shares.

Future Outlook

NA

Industry Context

This filing is specific to an individual's and related entities' ownership stake in Edesa Biotech, Inc. and does not provide broader industry trends or competitive analysis. It reflects an insider's increased commitment to the company.

Related Party Transactions

• Dr. Pardeep Nijhawan, the CEO and a reporting person, participated as a purchaser in the private placement of Series B-1 Convertible Preferred Shares from Edesa Biotech, Inc. on February 12, 2025.

Stakeholder Impact

• Shareholders: The increased insider ownership by Dr. Nijhawan may be viewed positively as a sign of management's commitment and confidence in the company's future. The private placement also provides capital to the company, which could support operations or strategic initiatives.
• Company: The capital raised through the private placement provides additional funding for the company's operations.

Key Dates

Keywords

Edesa Biotech, Pardeep Nijhawan, Schedule 13D, Beneficial Ownership, Private Placement, Series B-1 Preferred Shares, Restricted Share Units, Insider Ownership, SEC Filing, Biotech, Common Shares, Convertible Preferred Shares